-

Shareholder Alert: Robbins LLP is Investigating CytoDyn Inc. (CYDY) on Behalf of Shareholders

SAN DIEGO & VANCOUVER, Wash.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating CytoDyn Inc. (OTC: CYDY) on behalf of shareholders to determine whether certain CytoDyn officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company.

If you suffered a loss due to CytoDyn Inc.'s misconduct, click here.

CytoDyn Inc. (CYDY) Misled Shareholders About the Viability of its Drug for the Treatment of COVID-19

CytoDyn is a biotech company that - prior to the COVID-19 pandemic - was focusing on the development and commercialization of the drug "Leronlimab" for the treatment of patients with HIV. Since the beginning of the COVID-19 pandemic, CytoDyn has aggressively touted Leronlimab as a treatment for COVID-19, including that it had sought emergency use authorization ("EUA") from the U.S. Federal Drug Administration ("FDA") and planned to move forward with Operation Warp Speed. This, in turn, caused CytoDyn's stock price to skyrocket. Having traded at less than $1 per share throughout 2019, CytoDyn's stock reached its peak on June 30, 2020, trading at over $10 per share. While the stock price was artificially inflated, insiders dumped millions of shares for almost $26 million.

Thereafter, the Company's scheme began to unravel. On August 26, 2020, The Wall Street Journal reported that CytoDyn was not being considered for Operation Warp Speed. On September 16, 2020, CytoDyn's CEO admitted the Company had not actually made the request for EUA from the FDA. Beginning on March 5, 2021, the Company revealed that the primary endpoints of its Phase IIb/III data on Leronlimab was not statistically significant. On this news, CytoDyn's stock plummeted over several trading days, to close at just $2.35 on March 9. 2021.

CytoDyn Inc. (CYDY) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against CytoDyn Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

OTCBB:CYDY
Release Versions
English
$Cashtags
$CYDY
Hashtags
#ShareholderRights
#Shareholders
#StockMarket
#Stocks

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges PRIM Stockholders to Contact the Firm for Information About the Class Action Against Primoris Services Corporation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Primoris Services Corporation (NYSE: PRIM) securities between August 5, 2025 and June 22, 2026 (the "Class Period"). The lawsuit alleges that Primoris made materially false or misleading statements regarding the Company's cost forecasting, project oversight, and expected profitability of certain renewable energy constr...

EquipmentShare.com Stock Drop – If You Incurred Significant Losses Investing in EQPT Contact Robbins LLP for Information About Leading the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of shareholders who purchased or otherwise acquired EquipmentShare.com, Inc. (NASDAQ: EQPT) securities: (1) Class A common stock issued in connection with the Company's January 2026 initial public offering (“IPO”), or (2) EquipmentShare securities between January 23, 2026 and June 23, 2026, inclusive (the “Class Period”). EquipmentShare operates T3, an integrated cloud-based platfor...

MVST Stock Drop – Shareholders Who Suffered Significant Losses Should Contact Robbins LLP for Information About the Securities Class Action Against Microvast Holdings, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired Microvast Holdings, Inc. (NASDAQ: MVST) securities between April 1, 2025 and March 16, 2026, inclusive (the “Class Period”). The lawsuit alleges that Microvast Holdings, Inc. misled investors about its ability to achieve targeted profit margins and complete the expansion of its Huzhou, China manufacturing facility on sc...
Back to Newsroom